Lameness Repair Company

PetVivo Holdings, Inc. Adds Special Revenue Consultant Approaching Commercial Production

MINNEAPOLIS, Feb. 15, 2018 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (www.petvivo.com) (OTCMARKET:PETV) an emerging biomedical device Company, is moving Mr. David Merrill, a member of the Board of Directors, to cover the newly formed position of Special Revenue Consultant. His role under this title will be to oversee Marketing and Sales to successfully drive our product launch into meaningful revenues.

“Mr. Merrill’s enjoyed a 40+ year career in the Medical Device arena, serving as an executive at Medtronic, St. Jude and I-Flow Kimberly Clark. Merrill’s focus was on sales and market development internationally. He served as Vice President, CRM, Asia-Pacific at Medtronic, and Vice President, International, at I-Flow/Kimberly Clark,” stated Wes Hayne, PetVivo CEO. “As one of his first actions he is announcing the addition of Tami Wenthold to represent sales and market development in Minnesota. Tami will join representatives located in Nebraska, Ohio, and Arizona.”

“You can feel the momentum building. Our field sales team is booming with enthusiasm. Meetings have been scheduled with Key Opinion Leaders during the NVAC meeting later this week. It’s an exciting time to be a member of the Kush-PetVivo team,” Merrill stated.

First small batch processing to test the production format is expected to be produced within a week. Petvivo is using a date of mid-March to mid-April for commercial release. An independent sales team is being assembled along with training, market materials and the numerous items and issues that make up a typical product launch. Veterinaries should start hearing about the product with a soft launch through April and May 2018.

Company management and representatives have been attending industry trade shows in anticipation of the “Kush” product launch. Cynthia Sweatt, Office Director/Sales Co-Ordinator attended the Veterinary Meeting & Expo (VMX) show last week in Orlando, Florida. As the country’s largest trade show of its kind, it was previously called the North American Veterinary Community (NAVC) show. February 15-17 of this week, Wes Hayne (CEO), Randy Wenthold, (Chief Science Officer) and Cynthia Sweatt, (Office Director/Sales Co-Ordinator) will all be in attendance for the Minnesota Veterinary Medical Association (MVMA) in Rochester, Minnesota. During their stay in Rochester they will be spending a fair amount of time at Elite Custom Solutions, which will be hosting the manufacturing of “Kush”.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: 962-405-6216

Direct: (763) 443-7272

Source: Uptick Newswire

 

Source: PetVivo Holdings Inc.

PetVivo Holdings, Inc. Approaches Commercial Production

MINNEAPOLIS, Feb. 02, 2018 (GLOBE NEWSWIRE) — A long-awaited day is approaching for PetVivo Holdings, Inc. (www.petvivo.com) (OTCMARKETS:PETV), an emerging biomedical device company. We are speaking of commercial production after fourteen years of research and preparation. The excitement has been growing throughout the company and is expected to build through these final weeks.

PetVivo decided to move their production to Rochester, Minnesota working with “Elite Custom Solutions”, a very unique medical manufacturing facility. Mr. Samuel Probhakar, the CEO of Elite, along with PetVivo staffers Randy Wenthold, Chief Science Officer, and Donna Paddock, Laboratory & Production Manager, expect to have the labs set for production by the end of March (2018).

Randy Wenthold of PetVivo commented, “During the last several weeks, Donna Paddock and I with the support of PetVivo senior management have executed a contract manufacturing agreement with Elite Custom Solutions, started transfer of assembly documents to an ISO quality system and concluded clean room requirements with initial process layout. Moving into the new facility will begin next week, February 5th.”

The company was originally planning to install the manufacturing at its corporate headquarters in Edina, Minnesota but the available resources and capability to upscale production at Elite created a change in plans. Once discovered, the working relationship between PetVivo and Elite has grown daily.

Elite Custom Solutions is a design, development and manufacturing company specializing in medical products. In addition to manufacturing they are available to assist in the areas of material qualification, selection and development support, failure analysis and materials testing.

PetVivo Board member, Mr. David Merrill advised the move along with the hiring of Randy Wenthold, our Chief Science Officer.

“I’ve enjoyed a 5-year business relationship with Randy and am excited that he’s joined the PetVivo family. I’m also happy to endorse and support the decision to enlist Elite as our production fulfillment agent. My experience with Elite has been outstanding, and I welcome them to the PetVivo team.”

All the necessary segments are in place; Kush technology, a strong PetVivo leadership team, superb manufacturing support and an experienced dynamic distribution network.

“I’ve had the opportunity to visit with Randy’s wife Tami an equine Veterinary Technician, as well as a retired personal DVM friend, and they share my enthusiasm and confidence in endorsing Kush therapy, a therapy offering positive patient outcomes and positive economic benefits to our animal patients and the DVM community,” stated David Merrill, PetVivo Corporate Board Member.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch by the end of the fiscal year, March 2018.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wesley (Wes) C. Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Direct: (763) 443-7272

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, January 16, 2018 /EINPresswire.com/ — PetVivo Holdings, Inc. Adds Mr. Thomas Yezzi to Advisory Board.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

PRESS RELEASE

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Minneapolis, MN Jan. 16, 2018 PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company, is excited with the addition of Mr. Thomas Yezzi to the Advisory Board. Mr. Yezzi has over 20 years’ experience in the food ingredient and biotech industry, and has developed a broad network of venture partners, investors, and research scientists. His entrepreneurial focus has been on start-up and early stage companies. He is currently the President and Founder of Nu-Tek Products, a business incubator for wellness foods and life sciences ventures. He also serves as the President of two portfolio companies, Nu-Tek BioSciences and Nu-Tek Fibers.
Mr. Yezzi was a co-founder of Nu-Tek Salt. He served as President through the start-up and commercialization phases of the Company. His efforts contributed to sizeable funding from large VC’s such as Khosla Ventures.
Mr. Yezzi has also held senior management positions in Operations, Business Development, and Process Development. He was the Vice President of Operations at Protient, Inc., a value-added food ingredient company focusing on the fractionation and purification of milk, whey, and soy proteins. He helped build Protient into a successful food ingredient business using venture capital seed/start-up money. The company was sold in 2005 to one of Europe’s largest food companies. From 1993 to 2000, Mr. Yezzi was Director of Process and Product Development at Northern Food & Dairy, Inc., A SunOpta Company. He managed and generated new business in the nutraceutical, soy, and dairy industries. Tom successfully led many projects from the lab into commercial production. The company focused on custom/toll processing for large food companies such as Novartis, Dupont, Quaker Oats, Taiyo, White Wave, and Westbrae.
Mr. Yezzi holds Bachelor’s and Master’s degrees in Food Science from the University of Minnesota. His focus and research were in the areas of food and industrial microbiology.
“It is not only exciting but comfortably familiar having Mr. Yezzi as part of the team after having worked with him before. His skill sets are exceptional in the areas of manufacturing and scaling up. His background in microbiology and the work I have seen him previously involved with, adds greatly to the team that is setting up our labs and manufacturing capabilities.” Stated Wes Hayne, CEO of PetVivo Holdings, Inc.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 952-405-6216
Direct: (763) 443-7272

Wes Hayne
Petvivo Holdings, Inc.
952-405-6216
email us here

PetVivo Holdings, Inc. Airs on Fox Business Network

MINNEAPOLIS, Jan. 04, 2018 (GLOBE NEWSWIRE) — (OTCMARKETS:PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is happy to announce that the interview recently aired on the FOX Business Network, Saturday, December  23, 2017, at 3:00 PM Eastern/12:00 AM Pacific, on “New to the Street” is now available for viewing on demand on our company website www.petvivo.com and on the “New to the Street” YouTube channel  for those that may have missed the broadcast.

John Lai, President of Petvivo Holdings Inc. stated, “… that with the forthcoming launch of the Kush product and the impact that we are hoping for, it will bring a new quality of life to those dogs and horses we love. We are expecting a warm welcome with our product to the delivery of healthcare to the veterinary world. We felt it was important to bring it to the public at large and that television would be one of the best mediums to get the message out there. Therefore, we are proud to make available the interview on our website and through the New to the Street” YouTube channel.

FMW Media Works Corp. (“New To The Street“) is a leading provider of business profiles and special corporate programming. FMW Media Works produces “New to the Street” which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. “New to the Street” airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations. Visit www.NewToTheStreet.com.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: 952-405-6216

Direct: (763) 443-7272

Source: PetVivo Holdings Inc.

PetVivo Hires Randy Wenthold to Replace David Masters as Chief Technical Officer

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

PETVIVO HIRES MR. RANDY WENTHOLD AS CSO

MINNEAPOLIS, Dec. 28, 2017 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people has brought on Mr. Randy Wenthold into the position of Chief Science Officer. Mr. Wenthold will take over some of the responsibilities that Dr. Masters previously had on a day to day basis regarding product development, commercial production, and regulatory issues.

Dr. Masters has decided to resign from all his corporate positions with exception that he has chosen to remain as an active member of the Board of Directors of PetVivo Holdings, Inc.

“Now that the company is approaching commercial production, the addition of Mr. Wenthold into the position of Science Officer makes for a perfect fit. His experience in lab development and regulatory experience will allow us to address not only the initial production as scheduled, but also expand production capabilities given the success we expect with the launch of our first product,” stated PetVivo’s CEO, Wes Hayne.

Mr. Wenthold has been involved with medical devices from a development, manufacturing, and division management role for over 25 years. He was responsible for the development and market launch of the Renaflo acute renal failure family of filter products and Hemocor cardiosurgery fluid removal family of products (including the pediatric Junior device). Additional products he has developed are the Fibercor family of industrial filters, Vital Therapies ELAD and UFG filters, fiber used in an I-Flo drug delivery catheter, fiber or membranes used for implantable fiber devices and military water purification. Randy is named as the inventor of 3 patents and two provisional patents.

From 2012 until present he has been a medical device consultant specializing in the development of medical device products supporting cardiosurgery, sepsis and liver failure.

Mr. Wenthold stated, “I am excited to take on the role with Petvivo and build upon the previous contributions from Dr. Masters. I’m confident my previous experiences and expertise combined with those of the management team will contribute to the success planned for the company.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCMARKETS:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

Source: PetVivo Holdings Inc.

“New to the Street” Proudly Announces its Upcoming Telecast on FOX Business, Saturday, December 23, 2017 @ 3PM EST

Global Capital Network Investor Roadshow Begins in La Jolla

Source: Global Capital Network

LA JOLLA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — Global Capital Network (GCN) will conclude its year end work with emerging growth companies with it’s winter investor roadshow series in California.  The companies will present from December 5th to December 8th in La Jolla, Orange County, Santa Monica and San Francisco.  Companies include exemplary private start up and public emerging growth opportunities such as Herohl (www.herohl.com) and Petvivo (OTC:PETV).

Herohl is a nutritional supplement designed to combat bone and joint disease.  The CEO, Sabine Ohly, says of Herohl’s mission, “Over 50 million people are affected by arthritis in the United States and their biggest challenge is how to live a normal life and stay motivated while suffering from chronic pain, fatigue, physical and functional limitations as well as other consequences from chronic joint pain. Herohl’s goal is to provide them with an alternative, healthier and more affordable solution to painkillers with this new revolutionary dietary supplement.”

John Lai, founder of the Petvivo (PETV), an award winning osteoarthritis treatment for pets, notes of Petvivo’s growth, “Petvivo has made tremendous progress with additions to the board of directors, advisory board and the changes in management that have taken place in the last four months. First time commercial production is scheduled to start in December (2017), with sales and distribution underway to support the launch of our first product. Thus we will start concentrating on a goal of cash flow. Kush, our first product is aimed at the companion animal sector.”

Global Capital Network looks to host capacity audiences in each of its four locations.  The best performing part of the markets right now are micro-cap companies- the smallest of the small stocks. “You have a confluence of the reflation trade, rising rates, and the tax cut trade,” Martin Small, U.S. head of iShares at BlackRock has said, “All these things are positive for small- and micro-cap stocks.”  GCN looks to continue its work since 2010, working with hundreds of companies in markets across the US.

DISCLAIMER: Global Capital Network assists small to mid-sized emerging-growth public and private companies in gaining exposure and creating funding awareness. GCN conferences and investor roadshows are intended to provide FINRA broker/dealers, investment bankers, investment advisors, analysts, financial managers, fund managers, institutions, media and accredited investors with a forum for networking and communication.

Patrick A. Howell, phowell@sandiegoinvestmentconference.com, (949)813-1756 (c)

PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, November 21, 2017 /EINPresswire.com/ — Press Release PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals”
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
Created:
Tuesday, 11-21-2017
PRESS RELEASE
PETVIVO RECIEVES UPPIE AWARD FOR “BEST MEDICAL TECHNOLOGIES FOR HUMAN OR ANIMALS”.
PetVivo Holdings, Inc. OTCPINK: PETV (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce receiving the Uppie Award for “Best Medical Technologies for Human or Animals”, category. Prior to the award announcements, Petvivo was nominated for three categories; Best CEO, Best Medical Technologies for Humans or Animals and Best Scientific Medical Products.
“Petvivo continues to move forward. Our product is attracting the attention from both the investment and medical communities. The public is growing more aware of the company as we near our date for commercial production. We want to thank Uptick Newswire and the Uppie Awards for their recognition of our progress”, said Mr. Wes Hayne, CEO of Petvivo Holdings, Inc.
The Uppie Awards are produced by Uptick Newswire, an Investor Relations firm that provides services to publicly-traded micro-cap and nano-tech companies on the OTC, NYSE and CSE exchanges. The awards ceremony took place November 3rd, 2017 at the Flamingo Hotel in Las Vegas, Nevada, and was attended by micro-cap investors, boutique hedge-fund managers as well as local and national media outlets.
Mr. John Lai, the President of Petvivo Holdings, accepted the award, stating, “I want to thank the Academy…. opps, wrong city and speech (laughing). Seriously, I want to thank the Uppie Awards on behalf of the Company. It is an honor to accept this award. We look forward to next year.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

Press Release PetVivo Adds Mr. David Merrill to the Board of Directors

Eden Prairie, MN, Nov. 09, 2017 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCMARKETS: PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Mr. David Merrill has joined the Company’s Board of Directors.

Mr. Merrill is an accomplished Senior Executive in the Medical Device Industry. He is currently the CEO of the Merrill Family Enterprises, LLC (FME) which in different capacities gets directly involvedwith Medical Device companies.

: “I’m honored to join the PetVivo Holdings team. I evaluated the opportunity based upon the team’s leadership, fiscal responsibility, patent portfolio (existing and in process) and the science. Does the Science offer positive patient, medical professional and economic outcomes? PetVivo surpassed my expectations”

Mr. Merrill started his lengthy Medical Device career at Medtronic in 1973 selling implantable cardiac devices. After being inducted into the prestigious Medtronic’s President’s Club for his achievements, Merrill career expanded to District Manager then to Director, Sales Development, and Support in 1982. At that time, he moved to St. Jude Medical as Senior Director of their Southwest Region overseeing Direct and Independent sales representatives in 10 states. Roughly ten years from joining St. Jude he returned to Medtronic’s to be Vice President, Cardiac Rhythm Management, Asia-Pacific. He relocated to Hong Kong working internationally until his early retirement (30 Years) from Medtronic

After finding his retirement highly over rated he joined I-Flow as VP of International. During his time with I-Flow he negotiated distribution agreements throughout the UK, Scandinavia, Korea, Japan, Mexico, Brazil, Turkey, India, China etc., increased annual revenues and gross margins. The company was sold to Kimberly-Clark.In addition, Mr. Merrill has negotiated agreements with such medical giants as B. Braum, Fresenius-Kabi and Terumo.

“I first met David in High School some 50+ years ago in St. Paul, Minnesota. We lost track of each other from time to time, but reconnected a couple of months ago as we discussed an idea that David called me about regarding our product. One thing always leads to another. I am excited that after some 14,000,000 miles and at one time or another having worked in 53 countries David has decided to share his expertise in medical products and international distribution with PetVivo. In addition to the excitement, I know it will be fun having David around.” Stated Wes Hayne, PetVivo’s CEO.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 10-17-2017

PRESS RELEASE

 

PetVivo HOldings Provides Shareholder Update

 

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to provide an update to our shareholders.

 

Information and skilled execution has always led the way to success. It is important to us, the management team of your company, be committed to informing all shareholders of the progress that has been made and is currently underway. Several major steps forward have been taken in the last few months, and there is potentially more to come in the next few.

 

First, I will address the management changes and additions. I accepted the position of CEO and Board Member in June. At the end of August, Cynthia Jenkins joined the company as CFO. The month of September saw the addition of David Deming and Peter Vezmar to the Board of Directors. October solidified the addition of Robin Young and Michael Haider to the Advisory Board. All of the business biographies of these individuals are posted on our website (www.petvivo.com) .

 

Second, as a reporting company, PetVivo has continued the effort to catch up on delinquent filings. It is projected that the final filing to bring the company current with the Securities and Exchange Commission will be submitted in early November. Once current our financial results will be available at most financial web portals that provide financial data.

 

PetVivo has a new home that is in final construction in Edina, Minnesota. Corporate offices, Research and Commercial production facilities will be ready for full operation on December 1st. The first commercial runs of “Kush” will be supporting the sales and marketing roll out scheduled to commence at the same time. We are currently assembling the sales and distribution team that will introduce our first product.

 

Financial support for these activities comes from the completion and oversold round of $525,000 of financing, which ended only last week. The funding is expected to complete the construction and fund the early stages of market and sales.

 

The stock (PETV) has experienced considerable appreciation over the last six months as confidence by investors has grown with the company achieving specific benchmarks. The practice of goal setting, short term and long term has become the norm among the management of your company. We continue to push forward each and every day to make out products a primary component in the canine, equine and eventually human solutions for the future.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

 

 

 

 

 

 

 

 

 

Real Time Web Analytics